A meta-analysis of omega-3 fatty acids and incidence of atrial fibrillation

Journal of the American College of Nutrition

Volumn 31, Issue 1, 2012, Pages 4-13

  Khawaja, Owais ^a,b   Gaziano, J Michael ^a,b   Djoussé, Luc ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Arrhythmia; Fatty acids; Fibrillation; Inflammation

Indexed keywords

DOCOSAHEXAENOIC ACID; FISH OIL; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; PLACEBO; POLYUNSATURATED FATTY ACID; SOYBEAN OIL;

ARTICLE; CONFIDENCE INTERVAL; CORONARY ARTERY BYPASS GRAFT; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; META ANALYSIS; RECURRENT DISEASE; RISK; SCORING SYSTEM; SENSITIVITY ANALYSIS; UNITED STATES PREVENTIVE SERVICES TASK FORCE SCORING;

ATRIAL FIBRILLATION; FATTY ACIDS, OMEGA-3; FISH OILS; HUMANS; INCIDENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES;

EID: 84864940434     PISSN: 07315724     EISSN: 15411087     Source Type: Journal    
DOI: 10.1080/07315724.2012.10720003     Document Type: Article

References (61)

1. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society: ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing committee to revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation114:E257-E354, 2006.
2. GoAS, HylekEM, PhillipsKA, ChangY, HenaultLE, SelbyJV, SingerDE: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA285:2370-2375, 2001.
3. KannelWB, AbbottAR, SavageDD, McNamaraPM: Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med306:1018-1022, 1982.
4. FurbergCD, PsatyBM, ManolioTA, GardinJM, SmithVE, RautaharjuPM: Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol74:236-241, 1994.
5. PetersenP, GodtfredsenGJ: Atrial fibrillation: a review of course and prognosis. Acta Med Scand216:5-9, 1984.
6. PsatyBM, ManolioTA, KullerLH, KronmalRA, CushmanM, FriedLP, WhiteR, FurbergCD, RautaharjuPM: Incidence of and risk factors for atrial fibrillation in older adults. Circulation96:2455-2561, 1997.
7. WolfPA, AbbottAR, KannelWB: Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham study. Arch Intern Med147:1561-1564, 1987.
8. WolfPA, AbbottAR, KannelWB: Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke22:983-988, 1991.
9. KrahnAD, ManfredaJ, TateRB, MathewsonFA, CuddyTE: The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 98:476-484, 1995.
10. KannelWB, AbbottAR, SavageDD, McNamaraPM: Coronary heart disease and atrial fibrillation: the Framingham study. Am Heart J106:389-396, 1983.
11. GrimsgaardS, BønaaKH, HansenJB, MyhreES: Effects of highly purified EPA and DHA on hemodynamics in humans. Am J Clin Nutr68:52-59, 1998.
12. McLennanPL, BarndenLR, BridleTM, AbeywardenaMY, CharnockJS: Dietary fat modulation of left ventricular ejection fraction in the marmoset due to enhanced filling. Cardiovasc Res26:871-877, 1992.
13. GeleijnseJM, GiltayEJ, GrobbeeDE, DondersAR, KokFJ: Blood pressure response to fish oil Supplementation: metaregression analysis of randomized trials. J Hypertens20:1493-1499, 2002.
14. JamesMJ, GibsonRA, ClelandLG: Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr71:S343-S348, 2000.
15. AlbertCM, CamposH, StampferMJ, RidkerPM, MansonJE, WillettWC, MaJ: Blood levels of long-chain n-3 fatty acids and risk of sudden death. N Engl J Med346:1113-1118, 2002.
16. LeafA: The electrophysiological basis for the antiarrhythmic actions of polyunsaturated fatty acids. Eur Heart J3(Suppl D):D98-D105, 2001.
17. KangJX, LeafA: Prevention and termination of arrhythmias induced by lysophosphatidyl choline and acylcarnitine in neonatal rat cardiac myocytes by free omega-3 polyunsaturated fatty acids. Eur J Pharmacol297:97-106, 1996.
18. BillmanGE, KangJX, LeafA: Prevention of ischemia-induced ventricular arrhythmias by dietary pure n-3 polyunsaturated fatty acids in dogs. Circulation99:2452-2457, 1999.
19. SiscovickDS, RaghunathanTE, KingI, WeinmannS, WicklundKG, AlbrightJ, BovbjergV, ArbogastP, SmithH, KushiLH, CobbLA, CopassMK, PsatyBM, LemaitreR, RetzlaffB, ChildsM, KnoppRH: Dietary intake and cell membrane levels of longchain n-3 polyunsaturated fatty acids and risk of primary cardiac arrest. JAMA274:1363-1367, 1995.
20. MozaffarianD, RimmEB: Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA 296:1885-1899, 2006.
21. SavelievaI, K KakourosN, KourliourosA, CammAJ: Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace13:308-328, 2011.
22. SavelievaI, KakourosN, KourliourosA, CammAJ: Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention. Europace13:610-625, 2011.
23. HeidtMC, VicianM, StrackeSK, StadlbauerT, GrebeMT, BoeningA, VogtPR, ErdoganA: Beneficial effects of intravenously administered n-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a prospective randomized study. Thorac Cardiovasc Surg57:276-280, 2009.
24. MozaffarianD, PsatyBM, RimmEB, LemaitreRN, BurkeGL, LylesMF, LefkowitzD, SiscovickDS: Fish intake and risk of incident atrial fibrillation. Circulation110:368-373, 2004.
25. CaloL, BianconiL, ColivicchiF, LambertiF, LoricchioML, de RuvoE, MeoA, PandoziC, StaibanoM, Santini M: n-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol45:1723-1728, 2005.
26. FrostL, Vestergaard P: n-3 fatty acids consumed from fish and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Clin Nutr81:50-54, 2005.
27. HeidarsdottirR, ArnarDO, SkuladottirGV, TorfasonB, EdvardssonV, GottskalkssonG, PalssonR, IndridasonOS: Does treatment with n-3 polyunsaturated fatty acids prevent atrial fibrillation after open heart surgery?Europace12:356-363, 2010.
28. MacchiaA, MonteS, PellegriniF, RomeroM, FerranteD, DovalH, D’EttorreA, MaggioniAP, TognoniG: Omega-3 fatty acid Supplementation reduces one-year risk of atrial fibrillation in patients hospitalized with myocardial infarction. Eur J Clin Pharmacol64:627-634, 2008.
29. VirtanenJK, MursuJ, VoutilainenS, TuomainenTP: Serum longchain n-3 polyunsaturated fatty acids and risk of hospital diagnosis of atrial fibrillation in men. Circulation120:2315-2321, 2009.
30. BrouwerIA, HeeringaJ, GeleijnseJM, ZockPL, WittemanJC: Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation: the Rotterdam Study. Am Heart J151:857-862, 2006.
31. SaravananP, BridgewaterB, WestAL, O’NeillSC, CalderPC, DavidsonNC: Omega-3 fatty acid Supplementation does not reduce risk of atrial fibrillation after coronary artery bypass surgery a randomized, double-blind, placebo-controlled clinical trial. Circ Arrhythm Electrophysiol3:46-53, 2010.
32. BerryJD, PrineasRJ, van HornL, PassmanR, LarsonJ, GoldbergerJ, SnetselaarL, TinkerL, LiuK, Lloyd-JonesDM: Dietary fish intake and incident atrial fibrillation (from the Women’s Health Initiative). Am J Cardiol105:844-848, 2010.
33. NodariS, TriggianiM, CampiaU, ManerbaA, MilesiG, CesanaBM, GheorghiadeM, Dei Cas L: n-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study. Circulation124:1100-1106, 2011.
34. BianconiL, CaloL, MennuniM, SantiniL, MorosettiP, AzzoliniP, BarbatoG, BiscioneF, RomanoP, Santini M: n-3 polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: a randomized, double-blind, multicentre study. Europace 13:174-181, 2011.
35. KoweyPR, ReiffelJA, EllenbogenKA, NaccarelliGV, PrattCM: Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. JAMA304:2363-2372, 2010.
36. ShenJ, JohnsonVM, SullivanLM, JacquesPF, MagnaniJW, LubitzSA, PandeyS, LevyD, VasanRS, QuatromoniPA, JunyentM, OrdovasJM, BenjaminEJ: Dietary factors and incident atrial fibrillation: the Framingham Heart Study. Am J Clin Nutr 93:261-266, 2011.
37. MargosP, LeftheriotisD, KatsourasG, LivanisEG, KremastinosDT: Influence of n-3 fatty acids intake on secondary prevention after cardioversion of persistent atrial fibrillation to sinus rhythm. Europace 9:iii, 51, 2007.
38. SandesaraC, ChungMK, Van WagonerDR, BarringerTA, DulinM, KeithA, WaltsP, PasquiniJ, HopsonJ, FrancesF, WolbretteD, IsmailH, KendigA, ZimmermanM, MazurA, OlshanskyB: Fish oil to inhibit supraventricular arrhythmias after cardiac surgery: the FISH Trial. Paper presented at the Heart Rhythm Society’s 31st Annual Scientific Meeting, May 12-15, Session: Late-Breaking Clinical Trials II (Abstract), p 12e. Denver, 2010.
39. ErdoganA, BayerM, KollathD, GreissH, VossR, NeumannT, FranzenW, MostA, MayerK, TillmannsH: Omega AF study: Polyunsatuated fatty acids (PUFA) for prevention of atrial fibrillation relapse after successful external cardioversion (editorial). Heart Rhythm4:S185-S186, 2007.
40. Ozayd Kn M, Erdogan D, Tayyar S, Uysal BA, Dǒgan A, Içli A, Ozkan E, Varol E, Türker Y, Arslan A: n-3 polyunsaturated fatty acids administration does not reduce the recurrence rates of atrial fibrillation and inflammation after electrical cardioversion: a prospective randomized study. Anadolu Kardiyol Derg11:305-309, 2011.
41. JadadAR, MooreRA, CarrollD, JenkinsonC, ReynoldsDJ, GavaghanDJ, McQuayHJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary?Control Clin Trials17:1-12, 1996.
42. Harris R, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, Atkins D; Methods Work Group, Third US Preventive Services Task Force: Current methods of the Third US Preventive Services Task Force: a review of the process. Am J Prev Med20:21-35, 2001.
43. McLennanPL: Relative effects of dietary saturated, monounsaturated, and polyunsaturated fatty acids on cardiac arrhythmias in rat. Am J Clin Nutr57:207-212, 1993.
44. KangJX, LeafA: Antiarrhythmic effects of polyunsaturated fatty acids: recent studies. Circulation94:1774-1780, 1996.
45. McLennanPL, BridleTM, AbeywardenaMY, CharnockJS: Dietary lipid modulation of ventricular fibrillation threshold in the marmoset monkey. Am Heart J123:1555-1561, 1992.
46. XiaoYF, WrightSN, WangGK, MorganJP, LeafA: Fatty acids suppress voltage-gated Naþ currents in HEK293t cells transfected with the alpha-subunit of the human cardiac Naþ channel. Proc Natl Acad Sci U S A95:2680-2685, 1998.
47. LeafA, AlbertCM, JosephsonM, SteinhausD, KlugerJ, KangJX, CoxB, ZhangH, SchoenfeldD; Fatty Acid Antiarrhythmia Trial Investigators: Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation112:2762-2768, 2005.
48. ChristensenJH, GustenhoffP, KorupE, AarøeJ, ToftE, MøllerJ, RasmussenK, DyerbergJ, SchmidtEB: Effect of fish oil on heart rate variability in survivors of myocardial infarction: a double blind randomised controlled trial. BMJ312:677-678, 1996.
49. van Ravenswaaij-ArtsCM, KolleeLA, HopmanJC, StoelingaGB, van GeijnHP: Heart rate variability. Ann Intern Med 118:436-447, 1993.
50. SteinPK, BosnerM, KleigerRE, CongerBM: Heart rate variability: a measure of cardiac autonomic tone. Am Heart J127:1376-1381, 1994.
51. GeelenA, BrouwerIA, SchoutenEG, MaanAC, KatanMB, ZockPL: Effects of n-3 fatty acids from fish on premature ventricular complexes and heart rate in humans. Am J Clin Nutr81:416-420, 2005.
52. MarchioliR, BarziF, BombaE, ChieffoC, Di GregorioD, Di MascioR, FranzosiMG, GeraciE, LevantesiG, MaggioniAP, Mantini L, Marfisi RM, Mastrogiuseppe G, Mininni N, Nicolosi GL, Santini M, Schweiger C, Tavazzi L, Tognoni G, Tucci C, Valagussa F; GISSI-Prevenzione Investigators: Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation105:1897-1903, 2002.
53. HardarsonT, KristinssonA, SkuladottirG, Asvaldsdóttir H, Snorrason SP: Cod liver oil does not reduce ventricular extrasystoles after myocardial infarction. J Intern Med 226:33-37, 1989.
54. JenkinsDJ, JosseAR, BeyeneJ, DorianP, BurrML, LaBelleR, KendallCW, CunnaneSC: Fish-oil Supplementation in patients with implantable cardioverter defibrillators: a meta-analysis. CMAJ178:157-164, 2008.
55. ZhangZ, ZhangC, WangH, ZhaoJ, LiuL, LeeJ, HeY, Zheng Q: n-3 polyunsaturated fatty acids prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Int J Cardiol153:14-20, 2011.
56. TishinskyJM, MaDW, RobinsonLE: Eicosapentaenoic acid and rosiglitazone increase adiponectin in an additive and PPARgamma- dependent manner in human adipocytes. Obesity (Silver Spring)19:262-268, 2011.
57. McLennanP, HoweP, AbeywardenaM, MuggliR, RaederstorffD, ManoM, RaynerT, HeadR: The cardiovascular protective role of docosahexaenoic acid. Eur J Pharmacol300:83-89, 1996.
58. ChristensenJH, ChristensenMS, DyerbergJ, SchmidtEB: Heart rate variability and fatty acid content of blood cell membranes: a dose-response study with n-3 fatty acids. Am J Clin Nutr 70:331-337, 1999.
59. MadsenT, SkouHA, HansenVE, FogL, ChristensenJH, ToftE, SchmidtEB: C-reactive protein, dietary n-3 fatty acids, and the extent of coronary artery disease. Am J Cardiol88:1139-1142, 2001.
60. MoriTA, BaoDQ, BurkeV, PuddeyIB, BeilinLJ: Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. Hypertension34:253-260, 1999.
61. ErkkilaAT, MatthanNR, HerringtonDM, LichtensteinAH: Higher plasma docosahexaenoic acid is associated with reduced progression of coronary atherosclerosis in women with CAD. J Lipid Res47:2814-2819, 2006.